These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24895877)

  • 1. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
    Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
    Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
    Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.
    Kusakabe K; Yokoyama K; Ito K; Shibuya H; Kinuya S; Ito M; Higashi T; Togawa T; Koizumi K; Yoshimura M; Uchiyama M; Okamoto T; Kanaya S; Kanaya K; Yoneyama T; Ikebuchi H; Yanagida S; Shibata K; Segawa K; Yamamoto A
    Ann Nucl Med; 2012 May; 26(4):370-8. PubMed ID: 22450825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
    Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
    Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.
    Barrington SF; Kettle AG; O'Doherty MJ; Wells CP; Somer EJ; Coakley AJ
    Eur J Nucl Med; 1996 Feb; 23(2):123-30. PubMed ID: 8925845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
    Coover LR; Silberstein EB; Kuhn PJ; Graves MW
    J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid remnant ablation with 1110MBq of 131I in outpatients: measurement of effective dose to household members and establishment of safety precautions.
    Yoshimura M; Tsutsui H; Ikeda N; Koizumi K
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):101-8. PubMed ID: 23474638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial.
    Liu B; Kuang A; Huang R; Zhao Z; Zeng Y; Wang J; Tian R
    J Nucl Med; 2010 Apr; 51(4):618-23. PubMed ID: 20237029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
    Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
    Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 131I effective half-life and dosimetry in thyroid cancer patients.
    Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
    J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.
    Huić D; Medvedec M; Dodig D; Popović S; Ivancević D; Pavlinovic Z; Zuvic M
    Nucl Med Commun; 1996 Oct; 17(10):839-42. PubMed ID: 8951903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
    Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
    Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
    Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
    Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential third-party radiation exposure from patients undergoing therapy with 131I for thyroid cancer or metastases.
    D'Alessio D; Giliberti C; Benassi M; Strigari L
    Health Phys; 2015 Mar; 108(3):319-25. PubMed ID: 25627943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure.
    Gabriel S; Farman-Ara B; Bourrelly M; Carpentier O; Sebag F; Palazzo FF; De Micco C; Mancini J; Henry JF; Mundler O; Taïeb D
    Nucl Med Commun; 2011 Sep; 32(9):829-33. PubMed ID: 21633315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital discharge of patients with thyroid carcinoma treated with 131I.
    Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
    J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.